Oncomine Acute Myeloid Leukemia (AML) Panel

The Oncomine Acute Myeloid Leukemia (AML) Panel from Lab Tests Dubai is a cutting-edge, next-generation sequencing (NGS) assay designed to deliver rapid, comprehensive genetic insights into acute myeloid leukemia (AML) a fast-progressing blood cancer that requires immediate, precise intervention.

Using Ion Torrent™ NGS technology from Thermo Fisher Scientific, this highly sensitive panel analyzes over 30 clinically relevant genes associated with AML pathogenesis, prognosis, and treatment response including:

• ✅ FLT3 (ITD/TKD) – High-risk marker; targetable with midostaurin, gilteritinib
• ✅ NPM1 – Favorable prognosis when mutated (without FLT3-ITD)
• ✅ IDH1 / IDH2 – Targetable mutations (ivosidenib/enasidenib)
• ✅ CEBPA (biallelic) – Favorable risk indicator
• ✅ TP53, RUNX1, ASXL1, DNMT3A, KIT, JAK2, KRAS, PTPN11, KMT2A (MLL) – Prognostic and therapeutic markers

This test is essential for:

• Confirming AML diagnosis at the molecular level
• Performing risk stratification (favorable, intermediate, adverse)
• Guiding targeted therapies and FDA-approved inhibitors
• Enabling clinical trial eligibility
• Monitoring minimal residual disease (MRD) in remission

With results in just 10–14 working days, Lab Tests Dubai empowers hematologists and oncologists to make life-saving decisions faster so patients receive the right treatment at the right time.

Available through partner hematology centers, this test ensures accurate, reliable, and clinically actionable results—transforming complex genomic data into real-world cancer care.

Why You Need This Test

If you or a loved one has been diagnosed with acute myeloid leukemia (AML), this test could reveal the genetic drivers of the disease so your doctor can stratify risk, choose targeted drugs, and avoid ineffective chemotherapy.

You need the Oncomine AML Panel if:

• You’ve been diagnosed with de novo or secondary AML
• Your doctor is determining prognosis and treatment intensity
• You’re eligible for targeted therapy (e.g., gilteritinib for FLT3+)
• You’re being evaluated for stem cell transplant eligibility
• You’re considering clinical trials for relapsed/refractory AML
• You want molecular confirmation beyond morphology and flow cytometry

This test helps:

• Classify AML into risk groups (favorable, intermediate, adverse)
• Identify targetable mutations (FLT3, IDH1/2)
• Avoid aggressive chemo in elderly/frail patients if no benefit
• Guide post-remission therapy and MRD monitoring
• Support family counseling if germline predisposition suspected

Precision better survival, fewer complications.

Who Should Consider This Test?

The Oncomine AML Panel is recommended for:

• Newly Diagnosed AML Patients

Critical for initial risk assessment and treatment planning.

• Relapsed or Refractory AML Cases

To detect new mutations driving resistance.

• Patients Being Evaluated for Targeted Therapy

e.g., IDH inhibitors, FLT3 inhibitors.

• Candidates for Stem Cell Transplant

Adverse-risk genetics may justify early transplant.

• Hematologists & Oncologists

Seeking comprehensive molecular profiling for treatment decisions.

This test is now considered standard of care in modern AML management by ELN (European LeukemiaNet) and NCCN guidelines.

What Does the Test Reveal?

The Oncomine AML Panel detects:

• 🔬 Single Nucleotide Variants (SNVs) – e.g., IDH1 R132, TP53 R175
• 🔬 Insertions/Deletions (Indels) – including FLT3-ITD, a high-risk marker
• 🔬 Copy Number Variations (CNVs) – gene gains/losses
• 🔬 Gene Fusions – e.g., KMT2A (MLL) rearrangements
• 🔬 KMT2A-PTD (Partial Tandem Duplications) – poor prognosis

Key Clinical Implications

These findings directly impact treatment intensity, drug selection, and transplant decisions.

What Happens If You Skip Molecular Testing?

Without comprehensive NGS profiling, AML patients may:

• Be misclassified into wrong risk group → under/over-treatment
• Miss targeted therapies like gilteritinib or enasidenib
• Receive ineffective chemotherapy with severe side effects
• Be denied clinical trial access due to lack of biomarker data
• Experience relapse due to undetected resistant clones

The good news? AML is increasingly treatable with precision medicine:

• Midostaurin + chemo → improved survival in FLT3+ AML
• Ivosidenib → durable responses in IDH1-mutant AML
• Venetoclax combinations → effective in TP53-mutant cases

Early testing longer remission and better quality of life.

How to Prepare for the Test

To ensure accurate results:

• Peripheral Blood (EDTA) – during active disease

• Bone Marrow Aspirate (preferred for diagnosis/remission)

• FFPE tissue (if available)

• No fasting required

• Inform your doctor of:

• Current medications (e.g., hydroxyurea)

• Prior treatments or transplants

• Family history of blood disorders

Your hematologist will coordinate sample collection and submission to our partner lab.

Test Overview: Oncomine AML NGS Panel

Report Includes

• Detected mutations with variant allele frequency (VAF)
• ELN 2022 risk classification
• FDA/EMA-approved therapy recommendations
• Clinical trial eligibility flags
• Interpretation per international guidelines

Note: Often used alongside flow cytometry, cytogenetics, and PCR for full workup.

Benefits of the Oncomine AML Panel

• Guides Precision Treatment

Match patients to targeted drugs and protocols.

• Stratifies Risk Accurately

Favorable vs. adverse—critical for transplant decisions.

• Detects FLT3-ITD with High Sensitivity

Even at low VAF—missed by conventional PCR.

• Reduces Sequential Testing

One test replaces multiple single-gene assays.

• Supports Clinical Trials

Enables enrollment in novel therapy studies.

If you or a loved one is facing acute myeloid leukemia, the Oncomine AML Panel gives you the answers you need in 10–14 days.